← Leaderboards
Chad Daniel Huff
University Of Tx Md Anderson Can Ctr
$10,145,666
Attributed
$24,110,869
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,110,869 · 7
By mechanism
R01$24,110,869 · 7
Top collaborators
- Paul A Scheet6 shared
- Lisa A. Cannon Albright5 shared
- Michelle A T Hildebrandt5 shared
- Joellen M. Schildkraut5 shared
- Yuanqing Ye5 shared
- Hua Zhao5 shared
- Jennifer Below4 shared
- Philip Lupo3 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Kapil N. Bhalla$16,921,043
- Cielito C Reyes-Gibby$3,873,330
- Paul A Scheet$7,895,863
- Wendy A Woodward$3,444,065
- Abenaa M Brewster$1,367,215
Others in their field
Top investigators on “Variant”
- Richard A Gibbs · Baylor College Of Medicine$367,607,426
- Richard K. Wilson · Washington University$295,336,569
- Stacey Gabriel · Massachusetts Institute Of Technology$169,231,712
- David Heimbrook · Leidos Biomedical Research, Inc.$125,120,179
- Heidi L Rehm · Broad Institute, Inc.$96,250,516
- Margaret A Pericak-Vance · Doheny Eye Institute$83,999,609
Research focus
VariantGenesRare VariantGenome Wide Association StudyMutationSusceptibility GeneMalignant NeoplasmsRisk VariantGeneticBasePredispositionAllelesUnited StatesPatternInsightGenome-WideTargeted SequencingHigh RiskScreeningExome SequencingGenetic Risk FactorResourcesSamplingDiagnosis
Grant awards (29)
Leveraging whole genome sequencing and functional genomic characterization to improve NSCLP gene discovery$645,034
R01 · FY2025 · DE
Integrating Epidemiologic and Genomic Data to Elucidate the Genetic Overlap Between Congenital Anomalies and Pediatric Cancer$466,814
R01 · FY2025 · CA · contact PI
Integrating Epidemiologic and Genomic Data to Elucidate the Genetic Overlap Between Congenital Anomalies and Pediatric Cancer$444,374
R01 · FY2024 · CA · contact PI
Integrating Epidemiologic and Genomic Data to Elucidate the Genetic Overlap Between Congenital Anomalies and Pediatric Cancer$483,022
R01 · FY2023 · CA · contact PI
Harnessing the power of genetic relatedness for disease gene discovery$626,531
R01 · FY2022 · GM
Harnessing the power of genetic relatedness for disease gene discovery$626,531
R01 · FY2021 · GM
Harnessing the power of genetic relatedness for disease gene discovery$621,762
R01 · FY2020 · GM
High-throughput sequencing to identify novel melanoma susceptibility genes$1,036,661
R01 · FY2019 · CA · contact PI
Discovery of Risk Loci and Genomics of Pancreatic Cancer through Exome Sequencing$997,116
R01 · FY2019 · CA
Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors$791,850
R01 · FY2019 · CA · contact PI
Harnessing the power of genetic relatedness for disease gene discovery$688,093
R01 · FY2019 · GM
High-throughput sequencing to identify novel melanoma susceptibility genes$1,075,363
R01 · FY2018 · CA · contact PI
Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors$1,008,680
R01 · FY2018 · CA
Next generation sequencing to identify novel colorectal cancer genes$648,710
R01 · FY2018 · CA · contact PI
Discovery of Risk Loci and Genomics of Pancreatic Cancer through Exome Sequencing$3,203
R01 · FY2018 · CA
Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors$1,225,214
R01 · FY2017 · CA
High-throughput sequencing to identify novel melanoma susceptibility genes$1,075,388
R01 · FY2017 · CA · contact PI
Discovery of Risk Loci and Genomics of Pancreatic Cancer through Exome Sequencing$1,028,501
R01 · FY2017 · CA
Next generation sequencing to identify novel colorectal cancer genes$662,090
R01 · FY2017 · CA
Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors$1,200,669
R01 · FY2016 · CA
Discovery of Risk Loci and Genomics of Pancreatic Cancer through Exome Sequencing$1,125,781
R01 · FY2016 · CA
High-throughput sequencing to identify novel melanoma susceptibility genes$1,075,017
R01 · FY2016 · CA · contact PI
Next generation sequencing to identify novel colorectal cancer genes$669,923
R01 · FY2016 · CA
Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors$1,234,720
R01 · FY2015 · CA
Discovery of Risk Loci and Genomics of Pancreatic Cancer through Exome Sequencing$1,125,781
R01 · FY2015 · CA
High-throughput sequencing to identify novel melanoma susceptibility genes$1,090,017
R01 · FY2015 · CA · contact PI
Next generation sequencing to identify novel colorectal cancer genes$669,816
R01 · FY2015 · CA
Discovery of Risk Loci and Genomics of Pancreatic Cancer through Exome Sequencing$1,100,589
R01 · FY2014 · CA
Next generation sequencing to identify novel colorectal cancer genes$663,619
R01 · FY2014 · CA